Joel Braunstein

, MD, MBA

CEO, C2N Diagnostics

Dr. Braunstein is Co-Founder and CEO of C2N Diagnostics, a molecular diagnostics and therapeutics company spun out of the neuroscience laboratories of Drs. David Holtzman and Randall Bateman at the Washington University School of Medicine, St. Louis, Missouri. Dr. Braunstein has played a senior executive role in numerous emerging life sciences companies since 2004. He received his M.D. with Highest Distinction from Northwestern University Medical School in 1996. Subsequently, he trained in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School, and was a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Additionally, he completed an MBA with management and health policy focus and maintained an Assistant Professorship in Cardiology at Johns Hopkins University. In 2010, he was named a Distinguished Alumnus of Johns Hopkins University.

Read more

This Speaker's Sessions

Town Hall
Tuesday Oct. 20
2:00 PM
ET
Watch Replay
Now Live!

On the Path to 2025: Treatments and Diagnostics to Change the Trajectory of the Disease

What are the latest innovations in the drug pipeline?  How important is the need to develop diagnostics that can improve diagnosis and draw more patients into clinical trials, especially patients at high risk of Alzheimer’s? The panel will underscore the critical importance of progress on detection, diagnosis, research and treatments to stop Alzheimer’s. Key question: Will the U.S. meet our national goal of preventing and effectively treating Alzheimer's disease by 2025?

View SessionWatch Replay